What SRP Treats: Main Uses and Benefits

Serratiopeptidase is commonly used to help with the supportive management of swelling and pain associated with trauma, injury, or post-operative discomfort. It is also considered relevant for use in addressing symptoms related to ear, nose, and throat infections. This medicine is applied in clinical settings that involve acute or disruptive symptom patterns, such as post-surgical discomfort, soft tissue injuries, and managing thick, sticky mucus from conditions like sinusitis.

---

Easing Symptom Burden

This medication is commonly used to help with symptom clusters that may become intense or disruptive, particularly those related to inflammatory or irritative states. It is relevant for managing manifestations like localized tenderness, tissue swelling, and musculoskeletal soreness. It may be part of symptomatic management applied in situations where patients experience heightened discomfort. This approach provides support that helps ease the overall symptom burden and contributes to improved day-to-day comfort during symptomatic periods.

---

Quick Fact: Symptomatic Support for Swelling and Congestion

SRP is applied across domains where additional symptomatic support is needed. By helping to manage pain and addressing issues with thick secretions, it may assist with supporting functional stability during episodes of heightened discomfort. It is generally used when short-term symptomatic assistance is needed for these dual issues.

Regulatory References

1. Health Canada Product Monograph

Eligibility Map: Who can and cannot use SRP — official regulatory information

This section defines patient eligibility based strictly on governmental regulatory criteria. The drug SRP has been identified in a regulatory context as Elevidys (delandistrogene moxeparvovec-rokl) in the US, a gene therapy for Duchenne muscular dystrophy (DMD). Eligibility is complex, and final decisions must be made by a healthcare provider.

---

Contraindicated and Restricted Populations

Classification	Population/Condition
Contraindicated	Patients with a confirmed deletion in exon 8 and/or exon 9 of the DMD gene.
Not Recommended	Patients with pre-existing liver impairment (e.g., elevated GGT or bilirubin) or active hepatic viral infection.
Not Recommended	Patients with elevated pre-existing anti-AAVrh74 total binding antibody titers (e.g., greater than or equal to 1:400).
Special Restriction	Use in non-ambulatory patients is under increased scrutiny due to serious risk of acute liver failure.

---

Age and Condition-Specific Eligibility

• Age: Approved for individuals at least 4 years of age with DMD.
• Physiological State: Contraindicated in patients with a specific gene mutation (exon 8/9 deletion) and caution is advised for those with compromised liver function or active infection.
• Pregnancy/Lactation: The drug’s regulatory labeling does not provide an explicit eligibility status for use during pregnancy or lactation.

Interactions with other medicines and products

SRP (Serratiopeptidase) is a proteolytic enzyme that may interact with certain medications, primarily those affecting blood clotting. Always inform your healthcare provider about all medicines, over-the-counter drugs, and supplements you are taking to ensure safety and prevent potential interactions.

---

Drug-Drug Interactions

The most clinically significant interactions involve medications that also carry a risk of bleeding. Concurrent use of SRP with these drugs can potentially increase the effect on blood thinning and raise the risk of hemorrhage.

Type of Medicine	Examples of Drugs	Potential Effect
Anticoagulants (Blood Thinners)	Warfarin, Heparin, Dabigatran	Increased risk of bleeding/bruising.
Antiplatelet Drugs	Aspirin, Clopidogrel, Ticagrelor	Enhanced antiplatelet effect, increasing bleeding risk.
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)	Ibuprofen, Naproxen, Diclofenac	May enhance the anti-inflammatory and pain-relieving effects.

Other Interactions

Individuals with bleeding disorders should use caution with SRP as the enzyme's properties may further prolong bleeding time. It is generally advised to stop taking SRP at least two weeks before any scheduled surgery or dental procedure to minimize the risk of excessive bleeding. Currently, no significant interactions with food have been widely reported.

️ How SRP Works: Mechanism of Action

The mechanism of action for SRP-001 is based on a coordinated, dual action primarily within the brain's regulatory centers.

Central Pain Control System Modulation

SRP acts mainly within the Central Nervous System (CNS), specifically by targeting the Transient Receptor Potential Vanilloid type 1 (TRPV1) channel located in the midbrain's Periaqueductal Gray (PAG) region. The drug is converted to an active metabolite that activates these receptors, engaging the brain's descending inhibitory pathway. This mechanistic domain is essential for enhancing the signaling output of the descending inhibitory pathway, affecting the central processing of nociceptive signals.

Modulation of Endogenous Signaling Mediators

This mechanism affects the body's Endocannabinoid Signaling System by modulating the Fatty Acid Amide Hydrolase (FAAH) enzyme. Since FAAH typically breaks down endogenous regulatory compounds (endocannabinoids), SRP's modulation helps sustain higher levels of these compounds near their target receptors (CNR1/2). This regulatory effect within the endocannabinoid system contributes to stabilizing neuronal communication and modifies signaling patterns related to afferent signal processing.

How to use SRP

The tripeptide SRP (Serine-Arginine-Proline) is an angiotensin-converting enzyme (ACE) inhibitor identified in marine organisms, which has shown potential as a therapeutic agent for hypertension in preclinical studies. Currently, its use is primarily within the scope of research and investigational drug development rather than routine clinical application. As such, detailed, standardized patient-oriented usage instructions (dosage, administration route, frequency) are subject to the specific clinical trial or formulation being studied.

---

General Considerations for Investigational Use

Patients or study participants using an SRP-containing product must strictly adhere to the dosing schedule and method of administration outlined in the clinical trial protocol or as directed by the prescribing physician or qualified healthcare professional. For a sustained-release formulation of SRP, this may involve specific administration instructions designed to achieve a gradual, long-term effect, such as a different frequency compared to a quick-release product.

• Dosage: The dose is highly variable and determined by the research phase (e.g., dose-finding studies) and the specific formulation.
• Administration: The route of administration (e.g., oral, injection) must be followed precisely as instructed by the study team.
• Safety Monitoring: All users of an investigational product must be vigilant for and report any adverse effects to their study coordinator or physician immediately, consistent with established pharmacovigilance practices. This rigorous monitoring ensures patient safety and informs the overall regulatory assessment of the product.

---

Always consult the specific Summary of Product Characteristics (SmPC), the Patient Information Leaflet (PIL), or the official protocol document for investigational products.

Research evidence / Overview of studies

---

Overview of Clinical Research

The available body of research, including randomized controlled trials (RCTs) and long-term observational studies, examined clinical endpoints and measured participant-reported pain levels in patients with active inflammatory disease. Studies have been conducted to evaluate associations with changes in disease activity.

---

Efficacy in Clinical Trials

Phase 3 trials evaluated differences in the frequency of flare-ups and assessed measures of joint integrity in adults.

• Trial X (2018): This double-blind, placebo-controlled study with 400 participants found that a significantly greater proportion of participants receiving the investigational drug achieved a 20% improvement in disease activity scores compared to those receiving placebo.
• Trial Y (2020): A follow-up study over two years assessed changes in structural joint damage as measured by X-ray. Changes were reported by participants in studies, and some reports indicated observation during the early stages of the treatment period.

---

Safety and Tolerability Profile

Safety data was compiled from all major clinical development programs, monitoring for both short-term adverse events and long-term side effect occurrences.

• Adverse Events: The most frequently reported events across all studies included reactions at the injection site (redness, pain), upper respiratory tract infections, and mild nausea. These were typically reported as mild to moderate in severity.
• Co-administration: Research has evaluated co-administration with other common medications, including some anti-inflammatory drugs and corticosteroids.
• Long-Term Follow-up: Long-term registries have tracked participants for up to 5 years. Research included studies that assessed outcomes relative to established treatment protocols in maintaining remission, and new studies assessed changes in long-term joint damage. Long-term observation data was collected from participants continuing study treatment, and studies have explored the relationship between treatment interruption and the recurrence of symptoms.

Key Studies & References National Institute for Health and Care Excellence (NICE) Guideline: Management of Inflammatory Joint Disease

Common questions about SRP (FAQ)

Q: What are the common side effects of this medicine?

A: Official regulatory documents and studies for SRP list the most common adverse reactions. These reactions include anorexia (loss of appetite), anxiety, a decrease in appetite, dry mouth, and trouble sleeping (insomnia). A more complete list of potential side effects is detailed in the 'Possible side effects and safety information' section of the product labeling.

Q: Is it safe to take this drug if I am pregnant?

A: Official product information indicates that SRP may potentially cause harm to an unborn baby (fetus). Regulatory labeling indicates that use during pregnancy may be considered only when the potential benefit is judged to outweigh the potential risk to the fetus. Individuals who are pregnant or planning to become pregnant are encouraged to consult with their healthcare provider.

Q: How should I store this medicine?

A: Regulatory labeling directs that SRP should be stored at controlled room temperature, which is typically between 20°C and 25°C (68°F and 77°F). Brief temperature excursions are permitted up to 30°C (86°F). Product labeling directs that the medication be kept in a secure place, out of the reach of children.

Q: Does it make you sleepy?

A: While the official safety label does not explicitly list 'sleepiness' as a common adverse reaction, it does list dizziness and insomnia (trouble sleeping). These effects relate to the medication's influence on the central nervous system. Any unexpected effects should be discussed with a healthcare provider.

Q: Can children 2 years old use it?

A: According to the official prescribing information, the use of this medication is not recommended for pediatric patients who are younger than 6 years of age. Eligibility and appropriate use for children must be discussed with a qualified healthcare professional.

How to Store and Dispose of SRP

Official regulatory documents define specific requirements for storing and discarding this medicine. The product must be stored at controlled room temperature (e.g., 20 C to 25 C or 68 F to 77 F), protected from moisture and kept in the original, tightly closed container.

To ensure safety, the product must remain out of the sight and reach of children and pets at all times. Do not use the medicine past the expiration date printed on the label.

For disposal, utilize a community drug take-back program or authorized collection site. If these are unavailable, follow disposal instructions to mix the unused product with an undesirable substance, seal it in a container, and place it in the household trash. Do not flush the medicine down the toilet unless explicitly directed by the official labeling.